Stock CALT CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Pharmaceuticals

Delayed Nasdaq
Other stock markets
 15:54:00 10/06/2024 BST 		5-day change 1st Jan Change
39.4 USD -0.23% Intraday chart for Calliditas Therapeutics AB +0.13% +53.05%
06-07 European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
06-06 Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT

Business Summary

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Number of employees: 219

Sales per Business

SEK in Million2022Weight2023Weight Delta
Therapeutics for Renal Disease Immunoglobulin
90.1 %
376 46.8 % 1,087 90.1 % +189.58%
Outlicensing of Product
6.9 %
422 52.5 % 83 6.9 % -80.39%
Royalty
3.0 %
2 0.3 % 37 3.0 % +1,507.26%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
89.1 %
372 46.4 % 1,076 89.1 % +189.01%
Asia
7.6 %
287 35.7 % 91 7.6 % -68.10%
Europe
3.3 %
144 17.9 % 40 3.3 % -72.48%

Managers

Managers TitleAgeSince
Renée Aguiar-Lucander CEO
 Chief Executive Officer 62 17/05/17
Fredrik Johansson DFI
 Director of Finance/CFO 47 31/07/17
Richard Philipson CTO
 Chief Tech/Sci/R&D Officer 60 23/07/20
Krassimir Mitchev CTO
 Chief Tech/Sci/R&D Officer - 28/02/19
Johan Erik Häggblad CTO
 Chief Tech/Sci/R&D Officer 65 31/03/07
Åsa Hillsten IRC
 Investor Relations Contact - 31/03/23
Monika Tornsen PRN
 Corporate Officer/Principal 45 01-06
Christopher Ngai PRN
 Corporate Officer/Principal - 31/03/20
Frank Bringstrup LAW
 General Counsel 65 31/01/19
Sandra Frithiof HRO
 Human Resources Officer 49 10/07/22

Members of the board

Members of the board TitleAgeSince
Fred Driscoll BRD
 Director/Board Member 73 29/05/23
Henrik Stenqvist BRD
 Director/Board Member 57 31/12/21
Elmar Schnee CHM
 Chairman 65 07/05/19
Hilde Furberg BRD
 Director/Board Member 65 31/08/14
Margareta Elisabeth Björk BRD
 Director/Board Member 62 31/12/21
Diane Parks BRD
 Director/Board Member 71 07/05/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 59,580,087 40,690,384 ( 68.30 %) 5,908,018 ( 9.916 %) 68.30 %

Shareholders

NameEquities%Valuation
ASAHI KASEI CORPORATION
49.23 %
29,331,211 49.23 % 581 M $
LINC AB
10.01 %
5,962,312 10.01 % 118 M $
CALLIDITAS THERAPEUTICS AB
9.916 %
5,908,018 9.916 % 117 M $
BVF Partners LP
9.692 %
5,774,433 9.692 % 114 M $
Industrifonden
5.280 %
3,145,828 5.280 % 62 M $
Fjärde AP-fonden
4.470 %
2,663,000 4.470 % 53 M $
Unionen (Investment Management)
3.310 %
1,972,100 3.310 % 39 M $
Sofinnova Partners SAS
2.360 %
1,406,090 2.360 % 28 M $
E. Öhman J :or Fonder AB
2.230 %
1,328,635 2.230 % 26 M $
Renée Aguiar-Lucander
1.079 %
643,000 1.079 % 13 M $
NameEquities%Valuation
BVF, Inc.
2.518 %
750,000 2.518 % 30 M $
DWS Investment GmbH
0.1697 %
50,550 0.1697 % 2 M $
Ironwood Investment Management LLC
0.0856 %
25,511 0.0856 % 1 M $
Citadel Securities GP LLC
0.0490 %
14,594 0.0490 % 583 614 $
Susquehanna Securities LLC
0.0345 %
10,277 0.0345 % 410 977 $
Morgan Stanley Capital Services LLC
0.0201 %
5,986 0.0201 % 239 380 $
Desjardins Securities, Inc.
0.0134 %
3,985 0.0134 % 159 360 $
Wells Fargo Clearing Services LLC
0.0126 %
3,760 0.0126 % 150 362 $
Optiver Holding BV
0.008506 %
2,534 0.008506 % 101 335 $
Vision2020 Wealth Management Corp.
0.003934 %
1,172 0.003934 % 46 868 $

Holdings

NameEquities%Valuation
CALLIDITAS THERAPEUTICS AB
9.92%
 5,908,018 9.92% 116,955,951 $

Company contact information

Calliditas Therapeutics AB

D5, Kungsbron 1

111 22, Stockholm

+46 84 11 30 05

http://www.pharmalink.se
address Calliditas Therapeutics AB(CALT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

Ratings for Calliditas Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
208.2 SEK
Average target price
219.8 SEK
Spread / Average Target
+5.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+18.46% 80.5B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+15.08% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-18.33% 4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.39% 4.49B
YUHAN CORPORATION Stock Yuhan Corporation
+13.95% 4.44B
INDIVIOR PLC Stock Indivior PLC
+9.62% 2.19B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-28.40% 2.13B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+15.93% 2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-43.17% 1.78B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. CALT Stock
  5. Company Calliditas Therapeutics AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW